New research from the University of St Andrews, the University of Copenhagen and Drexel University has developed AI ...

QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...

Researchers at VIB and KU Leuven have identified a molecular process that allows motor neurons to maintain protein production ...

Health Canada has cleared the way for ALS patients in that nation to join the ongoing ALSTARS U.S. trial testing therapy candidate COYA 302.

IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer reported ...

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to muscle weakness and eventually death. While ...

“[…]we have identified FGF21 as a novel biomarker in ALS that is detected in multiple compartments including muscle, spinal cord, and circulation.” In this ...

A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...

A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

Please provide your email address to receive an email when new articles are posted on . A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it ...